Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This protocol will evaluate the feasibility and toxicity of dose-dense docetaxel followed by
doxorubicin and cyclophosphamide with support given as adjuvant or neoadjuvant treatment of
women with node positive and high risk breast cancer